IL17A and psoriasis vulgaris: In this real-world prospective cohort study, IL-17A inhibitors (SEC and IXE) and the IL-23 inhibitor GUS demonstrated significant efficacy in improving both nail and skin lesions in patients with plaque psoriasis.